Portal de investigación
Chip-AML22 Master Protocol: An Open-Label Clinical Trial in Newly Diagnosed Pediatric De Novo Acute Myeloid Leukemia (AML) Patients Including a Linked Phase II Trial with Quizartinib in FLT3-ITD/ NPM1wt Patients - a Study By the NOPHO-DB-SHIP Consortium
Fecha de publicación:
Fecha Ahead of Print:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Kaspers, Gertjan J. L.
- Wijnen, Noa E.
- Koedijk, Joost B.
- Ishimaru, Sae
- Benedictus, Renske
- Van Opstal, Ellen C.
- Van Tinteren, Harm
- Zwaan, C. Michel
- Biserna, Noha
- Downs, Pamela
- Duong, Yvonne
- Kamel, Yasser Mostafa
- Abrahamsson, Jonas
- Arad-Cohen, Nira
- Bodmer, Nicole
- Castillo, Luis
- Cheuk, Daniel
- Costa, Vitor
- De Moerloose, Barbara
- Fogelstrand, Linda
- Goemans, Bianca F.
- Hasle, Henrik
- Jonsson, Olafur G.
- Kovalova, Zhanna
- Munthe-Kaas, Monica C.
- Noren-Nystrom, Ulrika
- Palmu, Sauli
- Pasauliene, Ramune
- Saks, Kadri
- Tierens, Anne Maria
- Turkiewicz, Dominik
- Pronk, Cornelis Jan
Grupos
Abstract
Abstract no disponible
Datos de la publicación
- ISSN/ISSNe:
- 0006-4971, 1528-0020
- Tipo:
- Meeting Abstract
- Páginas:
- -
- Factor de Impacto:
- 4,834 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
BLOOD ELSEVIER
Citas Recibidas en Web of Science: 4
Documentos
- No hay documentos
Filiaciones
Filiaciones no disponibles
Campos de Estudio
Cita
Kaspers,GJL,Wijnen,NE,Koedijk,JB,Ishimaru,S,Benedictus,R,Van,EC,Van,H et al. Chip-AML22 Master Protocol: An Open-Label Clinical Trial in Newly Diagnosed Pediatric De Novo Acute Myeloid Leukemia (AML) Patients Including a Linked Phase II Trial with Quizartinib in FLT3-ITD/ NPM1wt Patients - a Study By the NOPHO-DB-SHIP Consortium. 65th Annual Meeting of the American-Society-of-Hematology (ASH). 2023. San Diego. RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS:ELSEVIER. 2023.